Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • OCTOBER 2020 Issue has been successfully launched on 1 October 2020.



Shethal Joju* and Alsa Ann George


Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a major public health issue in most of developing countries, despite scaling up interventions to achieve global control. Emergence of multi drug resistant TB (MDR-TB: organism resistant to isoniazid [INH] and rifampicin [RMP]) is a major hurdle for TB control programs especially in developing countries like India. The global report on drug resistance surveillance by the World Health Organization (WHO) estimated that 3.6% of new smear positive TB (NSP) cases and 20% of previously treated cases (PT) have MDR-TB. Fluoroquinolones (FQs) are a group of antibiotic that have tremendous activity against Mycobacterium tuberculosis (Mtb). They are bactericidal and enjoy a distinct status among second-line anti-tuberculosis (ATT) drugs due to their high oral bioavailability, good tolerability and low-to-moderate cost. In the last two decades, FQ mono-resistant strains of Mtb have emerged globally and the incidence have been increasing day by day. Resistance to second-line anti-TB drugs is a cause of grave concern for the community and tuberculosis control programmes. Mostly the patients with poor treatment outcomes are closely linked with presence of FQ resistance, this further complicates the case eventually leading to development of Extensively Drug-Resistant TB (XDR-TB).

Keywords: MDR TB, Fluroquinolone Resistance, XDR TB, Drug Resistant Tuberculosis.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More